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C URRENTLY pentobarbital is being used
in clinical trials for brain injury.
Smith et al.1 reported that 56 mg/kg pen-
tobarbital, administered prior to the uni-
lateral ligation of the middle cerebral ar-
tery (MCA), and light halothane and
thiopental, given just before or 15 mlii-
utes after ligation, significantly reduced
the amount of brain necrosis in dogs. Hoff
et al.2 found that when 90 mg/kg pento-
barbital was administered prior to liga-
tion, it reduced the extent of infarction
following permanent occlusion of the
MCA in baboons. Black et al.3 demon-
strated that pentobarbital is effective in
reducing brain necrosis when adminis-
tered 2 hours after the onset of ischemic
stroke in cats. Smaller doses of pentobar-
bital also may offer protection in ischemic
stroke when combined with other thera-
peutic maneuvers. For example, inhala-
tion of a gas mixture containing an in-
creased portion of 002 caused vasodilation
of cerebral blood vessels and an increase
in cerebral blood flow.4 In humans, high
doses of barbiturates produced deleterious
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cardiovascular and pulmonary effects, of-
ten with a fatal outcome.5 However, the
mortality of the mongolian gerbil, sub-
jected to a unilateral ligation of the com-
mon carotid artery under pentobarbital
anesthesia (60 mg/kg), was reduced from
65 per cent to 23 per cent by large doses
of dexamethasone (5 mg/kg) given intra-
peritoneally immediately after surgery
and again after 24 hours.6
In a previous study, we observed that
cats subjected to left middle cerebral ar-
tery (LMCA) occlusion remained anes-
thetized much longer with pentobarbital
anesthesia than cats given the same dose
of pentobarbital but not subjected to
LMCA occlusion.3 Furthermore, we had
observed that cats subjected to LMCA
occlusion and received both pentobarbital
and dexamethasone remained anesthetized
for approximately the same length of time
as control (sham-operated) cats treated
with the same dose of pentobarbital.3 We
suspected that these observed differences
might be due to an alteration of the phar-
macokinetics for pentobarbital under
these conditions. In the present study, we
determined the effect of acute ischemic
stroke in the cat on the pharmacokinetic
variables for pentobarbital with and
without the concurrent administration of
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dexamethasone. These findings were com-
pared with the pharinacokinetic param-
eters for pentobarbital from control
(sham-operated) cats. The pharmacoki-
netics for pentobarbital in normal healthy
cats recently were described by Wagner
et al.7 and were compared with that in
man.8#{176}
Material and Methods
Eighteen healthy adult cats, weighing
between 2.2 and 4.2 kg, were obtained
from the University Animal Care Facility
and utilized in the present study. Prior
to the surgical procedure, animals were
fed once daily with Purina Cat Chow
and water ad libitum.
During the three days before surgery
was performed, vital signs were obtained
periodically and behavior was assessed to
assure that the animals were healthy. Dur-
ing the surgical procedure, cats were para-
lyzed with succinyicholine and maintained
on a Harvard apparatus respirator (Mod-
el 607). Both femoral veins and a branch
of the femoral artery were cannulated
under local anesthesia with 2% lido-
caine. Femoral arterial pressure was
recorded continuously on a Grass poly-
graph (Model 7). The mean arterial pres-
sure was maintained at 105 mm Hg or
greater by replacement of all lost blood
with blood from donor cats. ECG leads
were implanted under the skin; animals
were placed in a reclining position and
were alternated from side to side at hour-
ly intervals. During experiments and
during surgery, cardiac rate and rhythm
were observed directly on a Tektronix
physiological monitor (Type 410), and
lead II of the ECG was recorded continu-
ously on a loiter monitor electrocardio-
corder (Avionics Model 400). These ECG
records subsequently were reviewed by
passing the magnetic tapes through an
Avionics composite electrocardioscanner
(Model 650).
Acute focal cerebral ischemia was pro-
duced in both experimental stroke groups
by ligation of the LMCA, utilizing a mod-
ification of the method of Sundt and
Waltz.’1 In the control group, the LMCA
was exposed surgically but ligation was
omitted. In each group, sodium pento-
barbital was administered as an intra-
venous bolus at a dose of 50 mg/kg. To
neutralize the highly basic pentobarbital,
a predetermined amount of hydrochloric
acid was injected at the same time as the
pentobarbital but in a different venous
cannula. Respiration was supported dur-
ing the surgical procedure and continued
after ligation of the LMCA for the entire
24-hour experimental period or until
spontaneous respiration occurred. The
three experimental groups differed in
management as follows:
Group I-Sham operation with sodium
pentobarbital administration. The LMCA
in these cats was exposed; however, liga-
tion was omitted.
Group II-Ischemic stroke with sodium
pentobarbital administration. Acute cere-
bral ischemia was produced by surgical
ligation of LMCA.
Group III-Ischemic stroke with sodi-
um pentobarbital and dexamethasone ad-
ministration. LMCA ligation was com-
pleted as for group II. However, 4 mg/kg
dexamethasone was administered intra-
venously prior to the production of is-
chemic stroke and every 6 hours there-
after for the entire 24-hour experimental
period.
Physiological saline was administered
intravenously throughout each experi-
ment to replace fluid losses, and hemato-
crits were maintained in the range of 26
to 40%; the normal range of hema-
tocrits for cats is 24 to 45%.12 Arte-
rial blood gases were measured hour-
ly during the 24-hour experimental pe-
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nod and were maintained within the fol-
lowing ranges: Pa02, 100 ± 25 mm Hg;
PaCO2, 28 ± 15 mm Hg; pH, 7.40 ± 0.05.
Rectal temperatures were maintained in
the range of 100 to 102#{176}F; the normal
range for cats is 1004 to 102.2#{176}F.’3
In cats of the two experimental groups
that were subjected to ischemic stroke,
brain lesions caused by the occlusion of
LMCA were verified by a previously de-
scribed procedure.3 Verification was based
on gross inspection of brain slices and
on histological study of hematoxylin-
and eosin-stained brain sections. The mar-
gin between infarcted and healthy tis-
sue was verified with light microscopy.
Arterial blood samples (2 ml) were ob-
tained at 0.083, 0.17, 0.33, 0.5, 0.75, 1.0,
1.5, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 20, and
24 hours after the intravenous admin-
istration of pentobarbital. The blood sam-
ples were placed in tubes containing
heparin as the anticoagulant. Each sample
of blood was centrifuged immediately
after collection at 2000 rpm for 10 min-
utes. The plasma was frozen and stored
in the frozen state until just prior to as-
say. The plasma pentobarbital concentra-
tions were determined utilizing the fol-
lowing gas-chromatographic method. Plas-
ma (0.5 ml) was acidified with 0.5 ml
1.ON hydrochloric acid, and mephobarbi-
tal solution was added as internal stand-
ard. Plasma was extracted with 6 ml
diethyl ether. The ether layer was dried
over anhydrous sodium sulfate and then
evaporated to dryness under nitrogen.
The residue was taken up in 200 to 300
l ether, and 1 to 6 l of the solution was
injected into the gas chromatograph. The
column was packed with 3% OV-17
on Gas Chrom Q, 100/120 mesh. Oper-
ating conditions were as follows: column
temperature, 186#{176}C; injector tempera-
ture, 240#{176}C; detector temperature, 240#{176}
C; nitrogen flow rate, 30 mi/mm; hydro-
gen flow rate, 14 mi/mm; air flow rate,
145 ml/min. The retention times were 2.7
and 6.5 minutes for pentobarbital and
mephobarbital, respectively. Determina-
tions are reported in units of micrograms
pentobarbital acid per milliliter plasma.
The plasma pentobarbital concentra-
tion-time data were processed with the
Fortran IV computer program CSTRIP14
in order to obtain the initial polyexpo-
nential parameter estimates. These esti-
mates were then improved by subjecting
them to a nonlinear least-squares analysis
by the use of the program NONLIN.’6
The i-test was utilized to determine sig-
nificant differences between parameters of
the experimental stroke groups and the
control group.
Results
The intravenous bolus of sodium pento-
barbital (50 mg/kg) was administered
simultaneous with ligation of the LMCA
in the two experimental groups (simu-
lated ligation in the control group). The
plasma pentobarbital concentration was
determined as a function of time over the
subsequent 24 hours. This relationship
was best described in most cats by the
sum of two exponential terms, where the
plasma concentration (Cr) is presented
as follows:
=A e’ + B e’ (1)
In eqs. (1) and (2), a > 6. It previously
had been demonstrated by us that at the
pentobarbital dose used in the present
study the pharmacokinetics for pentobar-
bital in cats are linear.7 Therefore, the
simple equations which apply to linear
systems were used in the present study for
calculations of pharmacokinetic param-
eters.16 Equation (2) was used for cal-
culation of the total area under the
plasma pentobarbital concentration-time
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TABLE I
Mean Values of Pharmacokinetic Variables for Pentobarbital in







































* Value in parentheses is S.D.
** The half-lives for groups I, II, and III were 12.3, 23.9, and 10.2 hours, respectively.
Equation (3) was used for calculation of
the clearance of pentobarbital from the




From Cli, and the rate constant /3, eq. (4)
was utilized to calculate the volume of
distribution of pentobarbital (Vd)’#{176}:
C’s
Vd-/3
The values of the pharmacokinetic vari-
ables for pentobarbital in each cat in
this study were obtained by computer
analysis and calculations with eqs. (2),
(3),and (4).
The mean values of pharmacokinetic
parameters ATJC, C1,, /3, and Vd for pen-
tobarbital in the two experimental stroke
(3) groups and in the control (sham-oper-
ated) group are presented in Table I.
Statistical comparisons of these mean
values utilizing the i-test are presented
in Table II. The AUG in group II (stroke
alone) is significantly larger than that in
(4) groups I (control) and III (stroke plus
dexamethasone administration). There is
no significant difference in AUG between
groups I and III. The plasma clearance
and elimination rate constant for pento-
TABLE II
Statistical Comparisons of Mean Values of Pharmacokinetic Variables















I and II P < 0.01 P.( 0.002 P < 0.01 P < 0.05
II and III P < 0.01 P < 0.01 P < 0.05 P> 0.5
I and III P> 0.1 P> 0.5 P> 0.5 P < 0.05
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barbital are significantly smaller in group
II than in groups I and III; there are
no significant differences in Cli, and /3 be-
tween groups I and III. The volume of
distribution of pentobarbital is signifi-
cantly smaller in groups II and III than
in group I; there is no significant differ-
ence in Vd between groups II and III.
The similarities between groups I and
III in AUG and /3 and the obvious differ-
ence of group II from groups I and III
in these parameters are readily seen in
Fig. 1. The slope of the plasma pentobar-
bital concentration-time curve is mark-
edly decreased by the presence of acute
ischemic stroke. However, when dexa-
methasone is administered prior to the
onset of ischemic stroke, the slope of the
plasma pentobarbital concentration-time















Certain physiological parameters were
measured throughout the experiments to
determine if they remained within nor-
mal limits or if there were any differences
between experimental groups. Arterial
blood pressures, blood gases, and hemato-
crits, measured before pentobarbital ad-
ministration and 12 and 24 hours after
pentobarbital administration, are pre-
sented in Table III. There is a modest
elevation in mean arterial blood pressure
before pentobarbital administration in
group I and at 12 hours after pentobar-
bital administration in groups I and II;
the normal range for arterial blood pres-
sure in adult eats is 77 to 123 mm Hg.’8
However, when tested by i-test, there was
no significant difference at any time
among the experimental groups in regard
to the magnitude of the blood pressure.
There were no significant differences
among the experimental groups in any of
the blood gas measurements except in the
P0C02 at 12 and 24 hours. At 12 hours
after dosing, groups II and III had de-
creased P0C02 values, and at 24 hours
only group III had a decreased PaCO2.
Hematocrits in all groups remained in
the normal range throughout the dura-
tion of the experiment. No significant
cardiac arrhythmias were seen in any of
the experimental animals. Cerebral in-
farction was verified histologically in all
animals of groups II and III. In sum-
mary, it appeared that none of the mea-
sured physiological parameters helped to
elucidate the mechanism by which is-
chemic stroke altered the pharmacoki-
netic parameters for pentobarbital.
2 0 6 8 10 2 10 16 II 20 22 20
TIMI (Housi)
Fig. 1. Semilogarithmic plot of plasma pento-
barbital concentration vs. time in selected rep-
resentative animals from each of the three ex-
perimental groups: (#{149})normals, group I;
(0) stroke and dexamethasone, group Ill;
(0) stroke only, group II.
This study demonstrated that acute is-
chemic stroke significantly alters the
values of the following pharmacokinetic
parameters for pentobarbital: A UC, Cl5,
/3, and V5. Ischemic stroke caused both a
decreased clearance and a decreased vol-
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TABLE III
Mean Arterial Blood Pressure, Blood Gases, and Hematocrit Before the
















































































































* Value in parenthesis is S.D.
** Elevated above normal range.
ume of distribution of pentobarbital.
These two factors together account for
the significantly increased AUG in cats
subjected to ischemic stroke alone (group
II). Plasma clearance is decreased be-
cause both the elimination rate constant
and volume of distribution are decreased;
this is true because plasma clearance is
the product of /3 and V5 [see eq. (4)].
The mechanism of change in pharma-
cokinetic parameters probably has its ba-
sis in marked cardiovascular changes
which are secondary to ischemic stroke.
We previously have demonstrated that
inyocardial damage is secondary to is-
chemic stroke, as evidenced by the pres-
ence in plasma of myocardial isoenzyme
(MB band) of creatine phosphokinase
(CPK) 19 Furthermore, we have shown
that cardiac output decreases and circu-
lating catecholamine concentrations in-
crease secondary to the onset of ischemic
stroke.2#{176} We previously have described a
shock-like syndrome of cardiovascular
origin secondary to the combined effects
of ischemic stroke and pentobarbital ad-
ministration.8
Benowitz and Meister2’ have reviewed
the effects of congestive heart failure and
increased sympathetic nervous system ac-
tivity (both of which can occur second-
ary to isehemic stroke) on the pharmaco-
kinetics of several drugs. The conse-
quences of these two conditions are a de-
creased volume of distribution of the
drug, a change in the blood flow pattern
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to various organs, and decreased hepatic
clearance of the drug. The decrease in
volume of distribution may be due to
shunting of blood away from organs that
are not vital and to decreased uptake of
drug by more slowly perfused tissues.2’
It has been demonstrated that pento-
barbital is metabolized by hepatic micro-
somes.22 It is in the latter subcellular
fraction where hydroxylation of the side
chain of pentobarbital occurs to produce
inactive oxidized pentobarbital.m For
drugs metabolized by the liver, systemic
drug clearance is generally considered to
be hepatic blood-flow dependent only
with those drugs that have high hepatic
intrinsic clearances? Pentobarbital does
not have a high intrinsic clearance. How-
ever, diseases that markedly alter the cir-
culation of the liver can compromise the
function of the liver and decrease the in-
trinsic clearance for a drug.23 This chain
of events could partially explain the de-
creased plasma clearance of pentobarbital
after the onset of ischemic stroke.
One further explanation for the pro-
longation of the half-life of pentobarbi-
tal after the onset of ischemic stroke
emerges from the theory of Brodie et al.
That is, the rate of uptake of pentobar-
bital by fat tissue determines the length
of action of the drug; in other words, the
more rapid the uptake of pentobarbital
by fat tissue, the shorter is the anesthetic
effect of the drug. One may substitute
“plasma concentration’’ for ‘‘anesthetic
effect” in this theory and apply it to the
present problem. Thus, the elimination
rate constant may be dependent in part
on the rate of uptake of the drug by fat
tissue. This hypothesis is supported by
the observation of Kitagawa25 that the
pentobarbital concentration in fat tissue
of the cat increased by 128 per cent from
the second hour to the sixth hour after
intraperitoneal injection of 70 mg/kg.
That is, the pentobarbital concentration
in fat tissue increased while the plasma
pentobarbital concentration decreased.
Consequently, if the cardiac output de-
creases as a result of the onset of is-
chemic stroke and results in decreased
blood flow to fat tissue and a decreased
rate of uptake of pentobarbital by fat
tissue, then the value of the apparent
elimination rate constant (/3) would be
less than normal. This would result in a
prolongation of the half-life of pentobar-
bital.
The mechanism of action of dexa-
methasone in the apparent reversion to
normal of the altered values of the phar-
macokinetic parameters for pentobarbital
after the onset of ischemlc stroke are
similarly speculative but are supported
by some reported observations. We have
already indicated that the combined ef-
fect of ischemic stroke and high-dose
pentobarbital treatment may result in
the tendency toward a circulatory shock-
like state.3 Harrison and Russel reported
that dexamethasone was effective in de-
creasing mortality in gerbils subjected to
ischemic stroke and in which pentobarbi-
tal had been administered.28 The mecha-
nism of action of dexamethasone prob-
ably is not in the prevention of the
development of brain ischemia itself, be-
cause dexamethasone does not reduce the
volume of brain infarction.27 It seems
probable that dexamethasone acts by
preventing the deleterious circulatory
changes which may occur secondary to
the combined effects of ischemic stroke
and high-dose pentobarbital treatment.
The use of glucocorticoids in circula-
tory shock has been reviewed recently by
Lefer and Spath.28 The protective hemo-
dynamic effects of glucocorticoids in cir-
culatory shock are the following: a posi-
tive inotropic effect, a vasodilator action,
and potentiation of the circulatory effects
of catecholamines.28 These effects are not
direct and can be demonstrated satisfac-
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torily only in the presence of circulatory
shock. How can these factors be applied
in the present study? Dexamethasone
treatment in group III could have pre-
vented the shunting of blood away from
major vascular beds (e.g., fat tissue).
Thus, that portion of change in the elimi-
nation rate constant due to abnormal dis-
tribution of pentobarbital after ischemic
stroke might be normalized. Further-
more, maintenance of normal hepatic cir-
culation might be accomplished by treat-
ment with dexamethasone; by this means
the intrinsic clearance of pentobarbital
would be maintained. In addition, it is
also possible that dexamethasone could
enhance the activity of the hydroxylating
enzyme directly, since glucocorticoids can
enhance the actions of certain enzymes.
All of the above hypotheses together
could explain the tendency toward nor-
malization of the altered AUC, Cl5, and
/3 after dexamethasone treatment in the
presence of ischemic stroke.
Dexamethasone treatment did not to-
tally correct the decreased volume of dis-
tribution (V5) of pentobarbital which oc-
curred in the presence of ischemic stroke.
However, although there was still a sig-
nificant difference in the mean V5 of
the control group (group I) and of
the dexamethasonetreated stroke group
(group III), there was a tendency of
Vd in group III toward that of group I.
Thus, it appeared that unlike the other
pharmacokinetic parameters, the de-
creased V5 produced by ischemie stroke
was not completely corrected by dexa-
methasone treatment.
Summary
The values of the pharmacokinetic
parameters for pentobarbital were deter-
mined in 18 cats, 12 of which were sub-
jected to acute ischemic stroke by liga-
tion of the left middle cerebral artery
(LMCA). All 18 cats received 50 mg/kg
sodium pentobarbital during operation.
The following three experimental groups
were formed: control (sham-operated);
ischemic stroke plus administration of 4
mg/kg dexamethasone; and ischemic
stroke without dexamethasone adminis-
tration. Ischemic stroke significantly pro-
longed the plasma half-life of pentobar-
bital, but concurrent administration of
dexamethasone prevented this effect. Is-
chemic stroke significantly reduced the
plasma clearance of pentobarbital, but
dexamethasone prevented this reduction.
Ischemic stroke significantly increased
the area under the plasma pentobarbital
concentration-time curve, but dexametha-
sone prevented this increase. Ischemic
stroke significantly reduced the volume
of distribution, but dexamethasone did
not prevent this reduction. The altera-
tions of the values of these pharmaco-
kinetic parameters for pentobarbital by
ischemic stroke and reversion to normal
by dexamethasone treatment are dis-
cussed in the light of certain known cir-
culatory changes which occur secondary
to ischemic stroke and dexamethasone
treatment.
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